A Trial of TTI-621 for Patients With Hematologic Malignancies and Selected Solid Tumours

Official Title

A Phase 1a/1b Dose Escalation and Expansion Trial of TTI-621, a Novel Biologic Targeting CD47, in Subjects With Relapsed or Refractory Hematologic Malignancies and Selected Solid Tumours

Summary:

Multicentre, open-label, phase 1a/1b trial of TTI-621 in subjects with relapsed or refractory hematologic malignancies and selected solid tumours.

Trial Description

Primary Outcome:

  • Frequency and severity of adverse events
This is a trial of TTI-621 in subjects with relapsed or refractory hematologic malignancies and selected solid tumours. TTI-621 (SIRPαFC) is a soluble recombinant fusion protein created by directly linking the sequences encoding the N-terminal CD47 binding domain of human SIRPα with the Fc domain of human immunoglobulin (IgG1). TTI-621 acts by binding human CD47 and preventing it from delivering an inhibitory "do not eat" (anti phagocytic) signal to macrophages. This trial will be conducted in 2 phases: Phase 1a (escalation phase) and Phase 1b (expansion phase). In the dose Escalation Phase (phase 1a), subjects with lymphoma will be enrolled in sequential dose cohorts to receive TTI-621 to characterize safety, tolerability, pharmacokinetics, and the maximum-tolerated dose (MTD). In the Expansion Phase (phase 1b), TTI-621 will be given to subjects with a variety of hematologic malignancies and selected solid tumours to further define safety and to characterize efficacy. In the Expansion Phase, the safety and efficacy of TTI-621 will also be assessed when it is given in combination with other anti-cancer drugs. The dose of TTI-621 to be delivered in the Expansion Phase of the study may be increased or decreased based on the subject's tolerability and on the subject's response to treatment.

View this trial on ClinicalTrials.gov

Interested in this trial?

Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.

Resources

Canadian Cancer Society

These resources are provided in partnership with the Canadian Cancer Society